A5042731311- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- Protein Kinase Regulation and GTPase Signaling
- Radiopharmaceutical Chemistry and Applications
- Lymphoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Cervical Cancer and HPV Research
- Nanoplatforms for cancer theranostics
- Melanoma and MAPK Pathways
- Colorectal Cancer Treatments and Studies
- Protease and Inhibitor Mechanisms
- Receptor Mechanisms and Signaling
- Bladder and Urothelial Cancer Treatments
- Thyroid Cancer Diagnosis and Treatment
- Nitric Oxide and Endothelin Effects
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Ubiquitin and proteasome pathways
Kunming Medical University
2023-2025
Banner MD Anderson Cancer Center
2017-2025
Lanzhou University
2025
Lanzhou University Second Hospital
2025
Banner Health
2021-2024
University of Arizona
2024
The University of Texas MD Anderson Cancer Center
2017-2024
Nur International University
2024
Goodyear (United States)
2012-2024
Shanghai Jiao Tong University
2019-2023
No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because mutation burden tumor is high and disease risk strongly associated with immunosuppression. In dose-escalation portion phase 1 study cemiplimab, a deep durable response was observed in patient metastatic carcinoma.We report results cemiplimab expansion cohorts patients locally or carcinoma, as well pivotal 2 cohort...
•First-in-human phase 1 study in patients with advanced solid tumors who received vibostolimab alone or pembrolizumab.•Vibostolimab plus pembrolizumab was well tolerated tumors.•Vibostolimab demonstrated antitumor activity tumors. BackgroundIn this first-in-human (NCT02964013; MK-7684-001), we investigated the safety and efficacy of anti-TIGIT (T cell immunoglobulin ITIM domain) antibody as monotherapy combination pembrolizumab.Patients methodsPart A enrolled tumors, part B non-small-cell...
Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between programmed cell death protein 1 (PD-1) on T-cells and PD-L1 PD-L2 tumour cells. A phase Ib trial of P plus chemotherapy was undertaken to evaluate safety efficacy. Patients with advanced, metastatic solid tumours were enrolled onto one six treatment arms. given: gemcitabine (G), G+docetaxel (D), G+nab-paclitaxel (NP), G+vinorelbine (V) or irinotecan (I) until progression toxicity, liposomal doxorubicin (LD) for up...
9517 Background: Patients (pts) with melanoma who progress on anti–PD-1 therapy (anti–PD-1–failed) have limited treatment options. RP1 is an HSV-1–based oncolytic immunotherapy expressing human GM-CSF and a fusogenic protein (GALV-GP-R−). Here, we present data from pts anti–PD-1–failed melanoma, including the initial cohort updated registration-directed (R-D) cohort, phase 1/2 IGNYTE study (NCT03767348). Methods: Pts had locally advanced or metastatic cutaneous ≥1 measurable injectable tumor...
Microtubule (MT) destabilization promotes the formation of actin stress fibers and enhances contractility cells; however, mechanism involved in coordinated regulation MTs cytoskeleton is poorly understood. LIM kinase 1 (LIMK1) regulates polymerization by phosphorylating depolymerization factor, cofilin. Here we report that LIMK1 also MT destabilization. In endothelial cells endogenous co-localizes with forms a complex tubulin via PDZ domain. induced thrombin or nocodazole resulted decrease...
Quavonlimab (MK-1308), a novel anti-CTLA-4 antibody, in combination with pembrolizumab was investigated phase I study.Dose-escalation (DE) phase: patients advanced/metastatic solid tumors received an initial flat dose of quavonlimab as monotherapy [25 mg (cohort 1), 75 2), or 200 3)] followed by four treatments the same plus every 3 weeks (Q3W). Dose-confirmation (DC): stage IIIB/IV non-small-cell lung cancer (NSCLC) first-line Q3W (arm A), 25 Q6W B), C), E)] pembrolizumab. Primary...
Abstract Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) a DLL3-targeting antibody-drug conjugate. Patients with NECs and other advanced DLL3-expressing were enrolled this phase I/II study (NCT02709889). The primary endpoint was safety. Two hundred patients enrolled: 101 NEC/NET (large-cell NEC, gastroenteropancreatic prostate cancer, NEC/NET) 99 (melanoma, medullary thyroid...
Rho GTPases integrate the intracellular signaling in a wide range of cellular processes. Activation these G proteins is tightly controlled by number guanine nucleotide exchange factors (GEFs). In this study, we addressed functional role recently identified p114RhoGEF vivo experiments. endogenous protein-coupled receptors with lysophosphatidic acid resulted activation transcription factor, serum response element (SRE), that was enhanced p114RhoGEF. This stimulation inhibited scavenger...
Abstract Background: CMP-001 comprises a CpG-A oligodeoxynucleotide packaged within virus-like particle. It is designed to activate tumor-associated plasmacytoid dendritic cells via TLR9 inducing an interferon-rich tumor microenvironment and anti-tumor CD8+ T cell responses. Materials Methods: CMP-001-001 ongoing phase Ib trial evaluating intratumoral (IT) in combination with pembrolizumab (administered per label) subjects advanced melanoma resistant (either did not respond or progressed) on...
Background: ESR1 mutation has recently emerged as one of the important mechanisms involved in endocrine resistance. The incidence and clinical implication not been well evaluated heavily pretreated breast cancer patients. Methods: We conducted a retrospective review advanced patients with tumors who underwent next-generation sequencing genomic profiling using Foundation One test at Cancer Treatment Centers America ® regional hospitals between November 2012 2014. Results: identified total 341...
Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing immunosuppressive effects of TIGIT. The addition vibostolimab to PD-1 inhibitor pembrolizumab has shown promising antitumor activity, warranting further exploration as potential therapeutic option. KEYVIBE program consists nine trials that will evaluate safety efficacy monotherapy vibostolimab-based combination therapy in advanced solid tumors hematological malignancies. These...
6005 Background: Treatment options are limited for patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) no approved treatment specifically targeting human papillomavirus (HPV) 16-positive tumors. In the first-line (1L) R/M setting, only a minority of (~20%) respond to pembrolizumab monotherapy, including those high programmed death ligand 1 (PD-L1) expression in tumor. HB-200 comprises an alternating sequence two replicating attenuated arenavirus vectors...
Rho family GTPases have been implicated in the regulation of endothelial permeability via their actions on actin cytoskeletal organization and integrity interendothelial junctions. In cell culture studies, activation RhoA disrupts junctions increases permeability, whereas Rac1 Cdc42 enhances barrier function by promoting formation restrictive The primary regulators proteins, guanine nucleotide dissociation inhibitors (GDIs), form a complex with GDP-bound monomeric G thus may serve as nodal...
Protein kinase A (PKA) is an important effector enzyme commonly activated by cAMP. The present study focuses on our finding that the vasoactive peptide endothelin-1 (ET1), whose signaling not coupled to cAMP production, stimulates PKA in two independent cellular models. Using vivo assay for activity, we found ET1 stimulated HeLa cells overexpressing receptors and aortic smooth muscle expressing endogenous levels of receptors. In these cell models, did stimulate indicating a novel mechanism...
RGS3 belongs to a family of the regulators G protein signaling (RGS). We previously demonstrated that cytosolic translocates membrane inhibit G<sub>q/11</sub>signaling (Dulin, N. O., Sorokin, A., Reed, E., Elliott, S., Kehrl, J., and Dunn, M. J. (1999) <i>Mol. Cell. Biol.</i> 19, 714–723). This study examines properties recently identified truncated variant termed RGS3T. Both RGS3T bound endogenous Gα<sub>q/11</sub> inhibited endothelin-1-stimulated calcium mobilization mitogen-activated...
9553 Background: RP1 is an enhanced potency oncolytic version of HSV1 that expresses human GM-CSF and the fusogenic protein GALV-GP R-. IGNYTE a multicohort phase 1/2 study evaluates safety efficacy in combination with nivo (NCT03767348) range tumor types. Preliminary data demonstrated durable anti-tumor activity tolerability for RP1+nivo. Here, we present updated results from initial melanoma (mel) anti-PD1 naïve non-melanoma skin cancer (NMSC) cohorts Methods: administered via intratumoral...
Abstract Melanoma is among the 10 most prevalent malignant tumors, posing a significant threat to human health. A detailed understanding of molecular mechanisms driving its progression crucial for advancing treatment strategies and outcomes. Based on bioinformatic analysis experimental validation, this study identified mitochondrial carrier homolog 2 (MTCH2) as key regulator melanoma proliferation. Mechanistically, MTCH2 enhanced expression nuclear translocation factor...
Abstract Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating antitumor activity inhibitors rearrangement-positive are limited. Here, a pan-cancer analysis &gt;46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic rearrangements ~0.04% cancers. Preliminary from phase 2 trial type I...
ABSTRACT Bladder cancer (BCa) is a highly invasive tumor with few successful therapies, and its unfavorable prognosis mainly stems from late diagnosis resistance to treatment. Ferroptosis type of non‐apoptotic cell death characterized by iron‐dependent regulated necrosis due extensive lipid peroxidation. Glycolysis fundamental metabolism, cells developing various strategies enhance this process. In study, we combined ferroptosis glycolysis gene sets, two biological processes closely related...